
Study Finds Costs of Biologic Drugs for Psoriasis Rose Between 2007 to 2021
New findings suggest that patients with commercial insurance who began first-line biologic treatments for plaque psoriasis saw average costs of therapies more than double from 2007 to 2021, pointing to more initiations of new interleukin (IL)-17 and IL-23 …